FDA Places Clinical Holds on Opdivo and Keytruda for Refractory Multiple Myeloma

The recent news are related to combinations of Opdivo (nivolumab) and Keytruda (pembrolilzumab) tested in clinical trials for patients with refractory multiple myeloma. Here is discussed the specific trials that have been halted for:

  • Opdivo (Ref.)
  • Keytruda (Ref.)

These drugs are some of the stars-drugs developed by some of the major pharmaceutical companies as part of the immunotheraphy wave of drugs to treat cancer. I already discussed shortly some of these drugs, here (Ref.).

The clinical trials have been halted due to large number of deaths that have occurred during the clinical trials.

This is important information given that private clinics around the world are using the anti PD1 drugs Opdivo and Keytruda as off-label drugs, possibly also in multiple myeloma patients.

Disclaimer:

This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.

Please read an extended version of the Disclaimer here: https://www.cancertreatmentsresearch.com/?page_id=1794

Related Articles


Leave a Reply

3 Comments on "FDA Places Clinical Holds on Opdivo and Keytruda for Refractory Multiple Myeloma"

Notify of
avatar
Pouya
Member